Portal Instruments is a clinical-stage medical device company, developing a needle-free drug injection platform for subcutaneous delivery of medication for patients suffering from chronic diseases such as ulcerative colitis, multiple sclerosis, rheumatoid arthritis and psoriasis.
Portal Instruments is a clinical stage, medical device company focused on the development and commercialisation of a needle-free injection platform. Portal’s technology is licensed from MIT (Cambridge, MA, US) and is being integrated into a connected drug delivery device for subcutaneous injection.
Portal Instrument’s Prime device offers:
- Needle-free delivery for increased comfort and safety
- Precise, accurate, software controlled delivery
- Connected technology
- Capability to handle high formulation viscosity.
Portal is start-up sized, based in Cambridge (MA, US) and is funded by series B venture capital. The company is privately owned.